MX2024007288A - Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. - Google Patents
Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.Info
- Publication number
- MX2024007288A MX2024007288A MX2024007288A MX2024007288A MX2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- methods
- amyloid beta
- tau
- beta protofibril
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291315P | 2021-12-17 | 2021-12-17 | |
| PCT/IB2021/000937 WO2023111618A1 (en) | 2021-12-17 | 2021-12-17 | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| PCT/US2022/079509 WO2023114586A1 (en) | 2021-12-17 | 2022-11-08 | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007288A true MX2024007288A (es) | 2024-06-28 |
Family
ID=84387973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007288A MX2024007288A (es) | 2021-12-17 | 2022-11-08 | Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250051427A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4448005A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024547001A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240115910A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022410770A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242280A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007288A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023114586A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025019457A1 (en) | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
| WO2025049938A1 (en) * | 2023-08-31 | 2025-03-06 | Florida Atlantic University Board Of Trustees | Non-invasive delivery method of antibodies to the brain for treatment of brain diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
| WO2020023530A2 (en) * | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CN112187401B (zh) | 2019-07-03 | 2022-06-14 | 华为技术有限公司 | 多时间单元传输方法及相关装置 |
| US11877315B2 (en) | 2020-09-15 | 2024-01-16 | Qualcomm Incorporated | Wireless device digital beamforming capability indication |
-
2022
- 2022-11-08 WO PCT/US2022/079509 patent/WO2023114586A1/en not_active Ceased
- 2022-11-08 CA CA3242280A patent/CA3242280A1/en active Pending
- 2022-11-08 JP JP2024536189A patent/JP2024547001A/ja active Pending
- 2022-11-08 EP EP22817858.8A patent/EP4448005A1/en active Pending
- 2022-11-08 AU AU2022410770A patent/AU2022410770A1/en active Pending
- 2022-11-08 MX MX2024007288A patent/MX2024007288A/es unknown
- 2022-11-08 KR KR1020247023419A patent/KR20240115910A/ko active Pending
- 2022-11-08 US US18/720,518 patent/US20250051427A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250051427A1 (en) | 2025-02-13 |
| CA3242280A1 (en) | 2023-06-22 |
| EP4448005A1 (en) | 2024-10-23 |
| WO2023114586A1 (en) | 2023-06-22 |
| AU2022410770A1 (en) | 2024-06-13 |
| KR20240115910A (ko) | 2024-07-26 |
| JP2024547001A (ja) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000199A (es) | ANTICUERPOS CONTRA AMILOIDE-ß CON PIROGLUTAMATO Y USOS DE ESTOS | |
| BR112022001460A2 (pt) | Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção | |
| CO2023011853A2 (es) | Anticuerpos anti-variable delta 1 de tcr | |
| CO2024013569A2 (es) | Moléculas de unión contra frα | |
| BR112021023024A2 (pt) | Anticorpo contra claudina 18a2 e uso do mesmo | |
| CR20190346A (es) | Conjugados de fármacos y anticuerpos anti-ccr7 | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| ECSP23003930A (es) | Anticuerpos de alta afinidad dirigidos a tau fosforilados en la serina 413 | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| BR112022001336A8 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
| BRPI0416141B8 (pt) | anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina | |
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CL2023003047A1 (es) | Anticuerpo anti componente del complemento 1s (c1s) | |
| UY39324A (es) | Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento. | |
| BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
| BR112023020622A2 (pt) | Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
| PY2018606A (es) | Anticuerpo monoclonal que se une específicamente a GITR | |
| CL2025001214A1 (es) | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos | |
| MX2022012913A (es) | Anticuerpo anti-ox40 y usos del mismo. | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| CL2023001667A1 (es) | Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos | |
| BR112021016596A2 (pt) | Anticorpo anti-pd-l1 e uso do mesmo | |
| CA3242280A1 (en) | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |